Do RNA Chemical Modifications Encode a Second Layer of Gene Regulation?
Do RNA chemical modifications such as m6A, m5C, pseudouridine, and A-to-I editing form a higher-order regulatory system that encodes transcript fate, ribosome specialization, and chromatin–RNA feedback loops? Explore three testable hypotheses on epitranscriptomic combinatorial codes, m6A–chromatin crosstalk in cancer apoptosis resistance, and rRNA modification-driven ribosome heterogeneity shaping stress-responsive translation.
Scientific Hypothesis Generation
Do RNA Chemical Modifications Encode a Second Layer of Gene Regulation?
Over 170 chemical modifications decorate RNA molecules in human cells, yet most remain poorly characterised in terms of function, coordination, and disease relevance. The epitranscriptome sits at the intersection of chromatin biology, translational control, and ribosome biology, raising questions that existing frameworks cannot answer.
Hypothesis 1
The METTL3-METTL14 writer complex functions as an integrated epitranscriptomic hub that maintains immune exclusion by simultaneously triggering YTHDF2-mediated decay of T-cell-recruiting transcripts and YTHDF1-mediated translation of MDSC-recruiting transcripts
The Gap
While individual m6A writers, readers, and erasers have been linked to immune cell infiltration in the tumour microenvironment, the coordinated mechanism by which a single writer complex simultaneously suppresses effector T cell recruitment and promotes myeloid-derived suppressor cell (MDSC) accumulation in colorectal cancer remains uncharacterised.
No study has tested whether METTL3 knockout simultaneously alters CXCL1 (MDSC-recruiting) and CXCL9/CXCL10 (T-cell-recruiting) chemokine axes, or whether this switch underlies resistance to anti-PD-1 therapy in microsatellite stable (MSS) CRC.
The Claim
The METTL3-METTL14 complex simultaneously maintains immune exclusion through two reader-dependent axes: YTHDF2-mediated degradation of Stat1 and Irf1 mRNAs (reducing CXCL9/CXCL10 secretion and thus CD8+ T cell recruitment) and YTHDF1-dependent translational enhancement of RELA (p65), which activates the NF-kB pathway to induce CXCL1-mediated recruitment of immunosuppressive G-MDSCs.
The coordination between these two axes collectively establishes an immune-excluded or immune-desert phenotype that characterises CRC resistance to PD-1 blockade. Genetic knockout of METTL3 should flip this dual switch, simultaneously decreasing CXCL1 and increasing CXCL9/CXCL10.
Why It's Testable Now
CRISPR/Cas9-generated METTL3-knockout and catalytically dead (D395A) variants in MSS CRC cell lines (e.g., CT26) combined with Ribo-seq for translational efficiency and RNA-seq for transcript stability enable locus-resolved dissection of the dual axis. Syngeneic mouse allografts with multi-colour flow cytometry and spatial transcriptomics directly measure the immune landscape shift.
The Intriguing Outcome
If confirmed, METTL3 would be established as a single druggable node that controls opposing chemokine programmes in CRC. Therapeutic inhibition of METTL3 could convert immune-desert tumours into immune-inflamed tumours, directly sensitising MSS CRC to anti-PD-1 immunotherapy.
This would reframe the epitranscriptomic writer not merely as a post-transcriptional regulator but as a master coordinator of the tumour immune microenvironment.
Thesis Entry Points
- Generate METTL3-KO and METTL3-D395A CT26 lines, perform paired Ribo-seq and RNA half-life measurements for RELA, Stat1, and Irf1, and quantify CXCL1, CXCL9, and CXCL10 secretion by multiplex ELISA.
- Implant WT and METTL3-KO CT26 cells into syngeneic BALB/c mice, treat with anti-PD-1, and profile CD8+ T cell and G-MDSC infiltration by multi-colour flow cytometry at days 7, 14, and 21.
- Deplete CD8+ T cells (anti-CD8) and MDSCs (anti-Ly6G) separately in METTL3-KO tumour-bearing mice to quantify the relative contribution of each recruitment axis to tumour regression.
Novelty Signal
Emerging: Individual arms (YTHDF2/Stat1 and YTHDF1/RELA) have been reported separately, but their coordinated function as a single METTL3-dependent recruitment switch has not been tested in any system.
Hypothesis 2
Tumour-intrinsic METTL3 establishes an immune-excluded microenvironment by acting as a dual-action recruitment toggle that initiates YTHDF2-dependent degradation of the effector-chemoattractant axis and YTHDF1-dependent translational activation of the suppressor-chemoattractant axis
The Gap
Existing studies have independently demonstrated that m6A modification destabilises Stat1/Irf1 transcripts and that YTHDF1 enhances RELA translation, but the two pathways have not been tested as components of a single integrated toggle in the same experimental system.
It remains unknown whether the chemokine secretome of CRC cells can be switched from a CXCL1-high/CXCL10-low state to a CXCL1-low/CXCL10-high state by a single genetic perturbation, and whether this switch is sufficient to restore anti-PD-1 responsiveness.
The Claim
In CRC, m6A modification of Stat1 and Irf1 mRNAs leads to their destabilisation and degradation via the m6A reader YTHDF2, resulting in significantly reduced secretion of the effector-recruiting chemokines CXCL9 and CXCL10. Simultaneously, RELA (p65) mRNA contains m6A sites recognised by YTHDF1, which enhances its translational efficiency and activates the NF-kB pathway to induce CXCL1 secretion for MDSC recruitment.
Genetic knockout of METTL3 in MSI-high CRC cells will switch their secretome from a CXCL1-high/CXCL10-low state to a CXCL1-low/CXCL10-high state. Furthermore, inhibiting USP5 will decrease RELA protein expression by destabilising YTHDF1, thereby reducing MDSC recruitment in vivo.
Why It's Testable Now
CRISPR/Cas9 METTL3-knockout and catalytically dead (D395A) variants in MSS CRC lines, combined with Ribo-seq for RELA translational efficiency and RNA-seq for Stat1/Irf1 stability, allow direct measurement of both axes. Syngeneic allografts with anti-PD-1 treatment and flow cytometry for CD8+ T cells and G-MDSCs link secretome changes to therapeutic responsiveness.
The Intriguing Outcome
Demonstrating that METTL3 functions as a binary toggle between effector and suppressor recruitment would identify a single molecular target whose inhibition converts immune-excluded CRC to immune-inflamed CRC. This would provide a mechanistic rationale for combining METTL3 inhibitors with anti-PD-1 therapy in MSS colorectal cancer, a subtype that currently shows minimal immunotherapy benefit.
Thesis Entry Points
- Perform paired Ribo-seq and RNA half-life measurements in METTL3-KO vs WT CT26 cells, quantifying translational efficiency of RELA and decay rates of Stat1/Irf1 transcripts simultaneously.
- Use a catalytically inactive METTL3 mutant rescue (D395A) to distinguish m6A-dependent regulation from m6A-independent scaffolding functions of the writer complex.
- Test USP5 inhibition in syngeneic CRC models to assess whether YTHDF1 destabilisation phenocopies the MDSC-reducing arm of the METTL3-KO phenotype without affecting the T-cell recruitment arm.
Novelty Signal
Emerging: The individual reader-dependent chemokine axes have been characterised, but their integration into a single METTL3-dependent toggle model and the prediction that USP5 inhibition selectively modulates one arm represent untested hypotheses.
Frequently asked questions
What are RNA chemical modifications?
RNA chemical modifications are covalent additions to RNA nucleotides that alter their structure and function without changing the underlying sequence. Over 170 types have been identified, including m6A, m5C, pseudouridine, and A-to-I editing. They regulate RNA stability, splicing, translation, and protein interactions.
What is the epitranscriptome?
The epitranscriptome refers to the complete set of biochemical modifications present on RNA molecules in a cell. It represents a post-transcriptional regulatory layer analogous to the epigenome on DNA. Epitranscriptomic marks are dynamic and reversible, installed and removed by dedicated writer and eraser enzymes.
How does m6A modification crosstalk with chromatin?
The m6A methyltransferase complex (METTL3/METTL14/WTAP) is recruited to chromatin co-transcriptionally, where specific histone marks such as H3K36me3 guide m6A deposition on nascent RNA. Conversely, m6A-marked transcripts can recruit chromatin remodellers back to DNA, creating a bidirectional feedback loop between histone and RNA modification states.
Can multiple RNA modifications co-occur on the same transcript?
Yes. Recent nanopore direct RNA sequencing studies show that individual transcript molecules can carry multiple distinct modifications simultaneously. Whether these co-occurring marks form a combinatorial code with predictable functional outputs is an active area of investigation.
What is ribosome heterogeneity?
Ribosome heterogeneity refers to the existence of structurally and functionally distinct populations of ribosomes within a single cell. Differences in rRNA modification patterns, ribosomal protein composition, and associated factors may produce ribosomes with different translational preferences or efficiencies.
How does BioSkepsis generate scientific hypotheses?
BioSkepsis synthesises peer-reviewed literature into structured research threads, identifies knowledge gaps and mechanistic unknowns, and formulates falsifiable hypotheses grounded in the existing evidence base. Each hypothesis specifies molecular entities, testable predictions, and experimental entry points.
What technologies enable single-molecule epitranscriptomics?
Oxford Nanopore direct RNA sequencing reads native RNA molecules without reverse transcription or amplification, preserving chemical modifications as electrical signal signatures. Combined with machine learning tools such as m6Anet, it enables detection of modification status at individual sites across single molecules.
Generate Hypotheses from Peer-Reviewed Literature
BioSkepsis synthesises published research into structured, testable hypotheses. Identify knowledge gaps, plan experiments, and accelerate your next grant application.
Start freeSources and further reading
- Lee H, Park YJ, Seo PJ. A new epigenetic crosstalk: chemical modification information flow. Genomics Genet Genom. 2023;1(1):e202200033. doi:10.1002/ggn2.202200033. PMID: 37829606
- Wang Y, Huang H, Chen J, Weng H. Crosstalk between histone/DNA modifications and RNA N6-methyladenosine modification. Curr Opin Genet Dev. 2024;86:102205. doi:10.1016/j.gde.2024.102205. PMID: 38759337
- Bailey AD, Talkish J, Ding H, et al. Concerted modification of nucleotides at functional centers of the ribosome revealed by single-molecule RNA modification profiling. eLife. 2022;11:e76562. doi:10.7554/eLife.76562. PMID: 35175196
- Xu Z, Xie T, Sui X, et al. Crosstalk between histone and m6A modifications and emerging roles of m6A RNA methylation. Front Genet. 2022;13:908289. doi:10.3389/fgene.2022.908289. PMID: 35783291
- Haussmann IU, Bodi Z, Sanchez-Moran E, et al. m6A potentiates Sxl alternative pre-mRNA splicing for robust Drosophila sex determination. Nature. 2016;540:301-304. PMID: 27919081
- Schwartz S, Bernstein DA, Mumbach MR, et al. Transcriptome-wide mapping reveals widespread dynamic-regulated pseudouridylation of ncRNA and mRNA. Cell. 2014;159(1):148-162. PMID: 25219674
- Huang H, Weng H, Zhou K, et al. Histone H3 trimethylation at lysine 36 guides m6A RNA modification co-transcriptionally. Nature. 2019;567:414-419. PMID: 30867593
- Hendra C, Pratanwanich PN, Poh YS, et al. Detection of m6A from direct RNA sequencing using a multiple instance learning framework. Nat Methods. 2022;19:1590-1598. PMID: 36357692